Medicenna Announces Results of Annual Meeting of Shareholders

Core Points - Medicenna Therapeutics Corp. held its annual meeting of shareholders on September 25, 2025, where all nominees listed in the management information circular were elected as directors [1][2] - A total of 55.75% of the issued and outstanding common shares were represented at the meeting [2] Election Results - Dr. Fahar Merchant received 35,539,547 votes (99.25% for, 0.75% against) - Mr. Albert Beraldo received 35,572,009 votes (99.35% for, 0.65% against) - Dr. John (Jack) Geltosky received 35,432,573 votes (98.96% for, 1.04% against) - Ms. Karen Dawes received 35,574,263 votes (99.35% for, 0.65% against) - Mr. Karim Lalji received 35,401,699 votes (98.87% for, 1.13% against) [2] Board Changes - Dr. John H. Sampson did not stand for re-election but will continue to support the company as a clinical advisor [3] - Mr. Albert Beraldo expressed gratitude for Dr. Sampson's service and ongoing support [3] Company Overview - Medicenna is focused on developing Superkines, including long-acting IL-2 Superkine MDNA11, which preferentially stimulates cancer-killing effector T cells and NK cells [4] - The company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials with over 130 patients, including a Phase 2b trial for recurrent GBM [4] - Bizaxofusp has received FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively [4] - Medicenna is also developing early-stage BiSKITs™ and T-MASK™ programs aimed at treating immunologically "cold" tumors [4]